logo UKRAIN®

can be reversed



Nowicky Pharma (FZE)

P.O. Box 48748,
Dubai Marina
United Arab Emirates

No: 01-01-02951

Inventor and patent owner
Dr. Wassil Nowicky
Margaretenstr. 7, A-1040 Vienna, Austria
Tel.: (+43 1) 586 12 23 Fax: (+43 1) 586 89 94



Studie VII

74 patients with prostatic carcinoma were involved in a controlled study at the Villa Medica Clinic (Edenkoben, Germany). These patients had already been treated according to all conventional therapy protocols, and due to relapse and/or progression of the disease had no further conventional options available. They were treated with UKRAIN, and partially at the same time with local hyperthermia, and the following results were obtained: complete remission in 73% of patients and partial remission in 22%, with only 5% of patients showing no effect on the progress of the disease ( 144, 192).


Depending on the general condition of the patient and the extent of the tumour, the best dosage of UKRAIN proved to be a stable one of 5, 10, 15 or 20 mg per injection daily or every second or third day. The toxins which are created by the regression of larger tumours can cause a poisoning of the whole body and worsen the general condition; this limits the application of UKRAIN at higher doses. In small doses, it was found that UKRAIN brings about improvement in the immune system. Higher doses bring about tumour regression ( 17).


Prognosis of standard treatment

From Wikipedia, the free encyclopedia

Prostate cancer rates are higher and prognosis poorer in Western societies than the rest of the world. Many of the risk factors for prostate cancer are more prevalent in the Western world, including longer life expectancy and diets high in animal fats. Also, where there is more access to screening programs, there is a higher detection rate. Prostate cancer is the ninth most common cancer in the world, but is the number one non-skin cancer in United States men. Prostate cancer affected eighteen percent of American men and caused death in three percent in 2005. In Japan, death from prostate cancer was one-fifth to one-half the rates in the United States and Europe in the 1990s.[57] In India in the 1990s, half of the people with prostate cancer confined to the prostate died within ten years. African-American men have 50-60 times more prostate cancer and prostate cancer deaths than men in Shanghai, China. In Nigeria, two percent of men develop prostate cancer and 64% of them are dead after two years.

In patients who undergo treatment, the most important clinical prognostic indicators of disease outcome are stage, pre-therapy PSA level and Gleason score. In general, the higher the grade and the stage, the poorer the prognosis. Nomograms can be used to calculate the estimated risk of the individual patient. The predictions are based on the experience of large groups of patients suffering from cancers at various stages.